share_log

藥明生物：翌日披露報表

WUXI BIO: Next Day Disclosure Return

香港交易所 ·  Apr 2 21:26
Summary by Futu AI
藥明生物技術有限公司（药明生物）於2024年4月2日向香港聯合交易所有限公司提交了翌日披露報表，披露了自2023年12月7日至2024年4月2日期間的股份購回活動。該公司在此期間進行了多次股份購回，但並未註銷這些股份。最新一次購回發生在2024年4月2日，當日購回705,000股，每股價格介於HKD 14.08至HKD 14.22之間，總計耗資約HKD 9,979,790。此外，該公司亦於同日根據股份期權計劃行使期權，發行了60,403股新股，每股發行價為HKD 1.89，較當日收市價HKD 14.3低約86.78%。自普通決議案通過以來，公司在香港聯交所購回的證券總數達86,612,000股，佔已發行股份的2.03869%。藥明生物確認，所有購回活動均符合香港聯交所的相關規則。
藥明生物技術有限公司（药明生物）於2024年4月2日向香港聯合交易所有限公司提交了翌日披露報表，披露了自2023年12月7日至2024年4月2日期間的股份購回活動。該公司在此期間進行了多次股份購回，但並未註銷這些股份。最新一次購回發生在2024年4月2日，當日購回705,000股，每股價格介於HKD 14.08至HKD 14.22之間，總計耗資約HKD 9,979,790。此外，該公司亦於同日根據股份期權計劃行使期權，發行了60,403股新股，每股發行價為HKD 1.89，較當日收市價HKD 14.3低約86.78%。自普通決議案通過以來，公司在香港聯交所購回的證券總數達86,612,000股，佔已發行股份的2.03869%。藥明生物確認，所有購回活動均符合香港聯交所的相關規則。
Pharmaceutical Biotechnology Co., Ltd. (Pharma Ming Biotech) filed a Next Day Disclosure Report with the Hong Kong Stock Exchange Limited on April 2, 2024, disclosing its share repurchase activities for the period from December 7, 2023 to April 2, 2024. The company has made several share repurchases during this period, but has not written them off. The most recent repurchase took place on April 2, 2024. 705,000 shares were repurchased on that date, priced between HKD 14.08 and HKD 14.22, with a total cost of about HKD 9,979,790. In addition, the Company issued 60,403 new shares on the same day, at HKD 1.89 per share, which was approximately 86.78% lower than the closing price of HKD 14.3 on the same day. Since the adoption of the Ordinary Resolution, the Company has repurchased 86,612,000 shares on the Hong Kong Stock Exchange, representing 2.03869% of the issued shares. Pharmacobiology confirms that all buybacks are in compliance with the relevant rules of the HKEx.
Pharmaceutical Biotechnology Co., Ltd. (Pharma Ming Biotech) filed a Next Day Disclosure Report with the Hong Kong Stock Exchange Limited on April 2, 2024, disclosing its share repurchase activities for the period from December 7, 2023 to April 2, 2024. The company has made several share repurchases during this period, but has not written them off. The most recent repurchase took place on April 2, 2024. 705,000 shares were repurchased on that date, priced between HKD 14.08 and HKD 14.22, with a total cost of about HKD 9,979,790. In addition, the Company issued 60,403 new shares on the same day, at HKD 1.89 per share, which was approximately 86.78% lower than the closing price of HKD 14.3 on the same day. Since the adoption of the Ordinary Resolution, the Company has repurchased 86,612,000 shares on the Hong Kong Stock Exchange, representing 2.03869% of the issued shares. Pharmacobiology confirms that all buybacks are in compliance with the relevant rules of the HKEx.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.